Table 3.

Subgroup analysis stratified by CAD of the associations between eGFR and LV structure and function.

eGFR (mL/min/1.73 m2)	All Patients		CAD		Non-CAD		P for Interaction
	aOR (95% CI)	p-Value	aOR (95% CI)	p-Value	aOR (95% CI)	p-Value
LV Hypertrophy
>90	Ref	-	Ref	-	Ref	-	0.519
61–90	1.23(1.07–1.42)	0.005	1.13 (0.95–1.33)	0.167	1.38 (1.04–1.83)	0.027
31–60	2.00 (1.64–2.45)	<0.001	1.85 (1.47–2.32)	<0.001	2.45 (1.57–3.87)	<0.001
16–30	3.87 (2.43–6.24)	<0.001	3.48 (2.11–5.84)	<0.001	6.85 (1.92–32.47)	0.006
≤15 or dialysis	4.66 (2.96–7.54)	<0.001	4.83 (2.98–8.07)	<0.001	3.98 (1.09–18.97)	0.06
P for trend	<0.001		<0.001		<0.001
LV Systolic Dysfunction
>90	Ref	-	Ref	-	Ref	-	0.348
61–90	1.53 (1.29–1.81)	<0.001	1.40 (1.16–1.70)	0.001	2.02 (1.37–3.01)	<0.001
31–60	2.67 (2.12–3.37)	<0.001	2.30 (1.77–2.97)	<0.001	4.96 (2.82–8.74)	<0.001
16–30	3.50 (2.11--5.75)	<0.001	2.90 (1.67–4.98)	<0.001	5.84 (1.46–21.38)	0.009
≤15 or dialysis	2.83 (1.76–4.52)	<0.001	2.62 (1.59–4.29)	<0.001	3.14 (0.62–13.01)	0.133
P for trend	<0.001		<0.001		<0.001
LV Diastolic Dysfunction
>90	Ref	-	Ref	-	Ref	-	0.779
61–90	1.26 (1.09–1.47)	0.002	1.14 (0.96–1.36)	0.132	1.54 (1.15–2.06)	0.004
31–60	2.08 (1.70–2.56)	<0.001	1.76 (1.39–2.22)	<0.001	3.12 (2.00–4.91)	<0.001
16–30	2.30 (1.46–3.65)	<0.001	1.95 (1.18–3.24)	0.010	4.29 (1.37–14.20)	0.013
≤15 or dialysis	6.74 (4.16–11.29)	<0.001	6.21 (3.49–10.85)	<0.001	7.72 (2.11–36.89)	0.004
P for trend	<0.001		<0.001		<0.001

Abbreviation: aOR, adjusted odds ratio; CAD, coronary artery diseases; CI, confidence interval; eGFR, estimated glomerular filtration rate; LV, left ventricular. Multivariable logistic regression was adjusted for multiple variables (age, gender, body mass index, diabetes mellitus, hypertension, congestive heart failure, high-density lipoprotein cholesterol, β-blockers, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker).